Achieving blood pressure goal: Initial therapy with valsartan/ hydrochlorothiazide combination compared with monotherapy

Journal of Human Hypertension

Volumn 24, Issue 12, 2010, Pages 823-830

  Weinberger, M H ^a   Glazer, R D ^b   Crikelair, N A ^b   Chiang, Y T ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

HCTZ; initial therapy; valsartan

Indexed keywords

HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; PLACEBO; VALSARTAN;

ADULT; ARTHRALGIA; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; ORTHOSTATIC HYPOTENSION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIURETICS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PLACEBO EFFECT; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE;

EID: 78649330003     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.17     Document Type: Article

References (32)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The Seventh Report of the Joint National Committee on Prevention Detection, Evaluation, Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003; 289: 2560-2572.
3. Douglas JG. Clinical guidelines for the treatment of hypertension in African Americans. Am J Cardiovasc Drugs 2005; 5: 1-6.
4. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al. Preserving renal function in adults with hypertension diabetes: a consensus approach. National Kidney Foundation Hypertension Diabetes Executive Committees Working Group. J Kidney Dis 2000; 36: 646-661.
5. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187. (Pubitemid 46924065)
6. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo Jr JL et al. Treatment of hypertension in the prevention management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research the Councils on Clinical Cardiology Epidemiology Prevention. Circulation 2007; 115: 2761-2788.
7. Elliott WJ. Is fixed combination therapy appropriate for initial hypertension treatment? Curr Hypertens Rep 2002; 4: 278-285.
8. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH et al. Success predictors of blood pressure control in diverse North American settings: the antihypertensive lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4: 393-404.
9. Mulvany MJ. The Fourth Sir George Pickering memorial lecture. The structure of the resistance vasculature in essential hypertension. J Hypertens 1987; 5: 129-136.
10. Suwa Na, T Takahashi. Morphological and Morpho-metric Analysis of Circulation in Hypertension and Ischaemic Kidney. Munich: Urban & Schwarzengerg, 1971.
11. Luscher TF, Vanhoutte PM, Raij L. Antihypertensive treatment normalizes decreased endothelium-depen-dent relaxations in rats with salt-induced hypertension. Hypertension 1987; 9: III193-III197.
12. Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27.
13. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
14. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886. (Pubitemid 36677151)
15. Staessen JA, Thijisq L, Fagard R, Celis H, Birkenhager WH, Bulpitt CJ et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004; 22: 847-857.
16. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160: 41-46.
17. Pool JL, Glazer R, Weinberger M, Alvarado R, Huang J, Graff A. Comparison of valsartan/hydrochlo-rothiazide combination therapy at doses up to 320/25mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007; 29: 61-73.
18. Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861-866.
19. Ruilope LM, Malacco E, Khder Y, Kandra A, Bonner G, Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005; 27: 578-587.
20. Franklin S, Lapuerta P, Cox D, Donovan M. Initial combination therapy with irbesartan/hydrochlorothia-zide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy. J Clin Hypertens (Greenwich) 2007; 9: 15-22.
21. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2158.
22. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328: 914-921.
23. Norris K, Neutel JM. Emerging insights in the first-step use of antihypertensive combination therapy. J Clin Hypertens (Greenwich) 2007; 9: 5-14.
24. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V et al. Benazepril plus amlodipine or hydrochlo-rothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
25. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816.
26. Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
27. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009; 54: 32-39.
28. Calhoun DA, Glazer RD, Pettyjohn FS, Coenen PD, Zhao Y, Grosso A. Efficacy and tolerability of combination therapy with valsartan/ hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin 2008; 24: 2303-2311.
29. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
30. Fine LJ, Cutler JA. Hypertension and the treating physician: understanding and reducing therapeutic inertia. Hypertension 2006; 47: 319-320.
31. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006; 47: 345-351.
32. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-719.